Quick Comparison
| Agmatine Sulfate | Noopept | |
|---|---|---|
| Half-Life | 2-3 hours | 30-60 minutes (active metabolite cycloprolylglycine persists longer) |
| Typical Dosage | Standard: 500-2000 mg daily in 1-3 doses. For mood: 1000-2000 mg. For pain: 1000-2500 mg. Take on empty stomach. Agmatine sulfate is the most common supplement form. May enhance the effects of some nootropics and medications — research interactions. | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. |
| Administration | Oral (powder, capsules). Take on empty stomach for best absorption. | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Agmatine Sulfate
Agmatine is a polyamine neuromodulator with multiple targets: (1) NMDA receptor antagonist at the polyamine binding site (GluN1/GluN2B) — reduces excitotoxicity, pain signaling, and blocks the receptor's open channel. (2) Imidazoline I1 and I2 receptor agonist — I1 in the rostral ventrolateral medulla reduces sympathetic tone; I2 modulates monoamine oxidase and provides anxiolytic/antidepressant effects. (3) Selective nNOS (neuronal nitric oxide synthase) inhibitor — reduces peroxynitrite formation and oxidative stress while preserving eNOS (endothelial) function for vascular health. (4) Alpha-2 adrenergic receptor agonist — reduces norepinephrine release from locus coeruleus, promoting calm. (5) Modulates opioid receptors — enhances mu-opioid analgesia, potentiates delta-opioid, and may reduce tolerance via nitric oxide and NMDA mechanisms.
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
Risks & Safety
Agmatine Sulfate
Common
Mild gastrointestinal discomfort, diarrhea at high doses.
Serious
May potentiate opioid medications (increased sedation risk). May lower blood pressure.
Rare
Headache, nausea.
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
Full Profiles
Agmatine Sulfate →
A metabolite of L-arginine produced by decarboxylation. Agmatine is an endogenous neuromodulator that acts on multiple receptor systems — it blocks NMDA receptors, activates imidazoline receptors, inhibits nitric oxide synthase, and modulates opioid signaling. This makes it useful for neuropathic pain, mood, stress resilience, and as a complement to other nootropics. Also enhances insulin sensitivity and nitric oxide production.
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.